Mirati To Encore Compelling Clinical Data Demonstrating Adagrasib's Potential as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors at 2023 ASCO Annual Meeting

/PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced presentations and posters to be shared at...

Related Keywords

United States ,American ,Alan Sandler ,Exchange Commission ,Additional Company Presentations Highlight Real ,Facebook ,Nasdaq ,Mirati Therapeutics Inc ,Twitter ,Linkedin ,American Society Of Clinical Oncology ,National Comprehensive Center Network ,Patients Living ,Mirati Therapeutics ,Clinical Oncology ,Annual Meeting ,Rapid Communication ,Central Nervous System ,Advanced Solid Tumors Harboring ,Rapid Abstract Updates Education ,Developmental Therapeutics ,Molecularly Targeted Agents ,Tumor Biology Poster ,Lung Cancer ,Non Small Cell Metastatic Poster ,Nc ,